---
type: "Nootropic"
title: "Omega-3 DHA/EPA"
description: "EPA and DHA are long-chain omega-3 fatty acids; DHA is an important brain membrane component. They are not a universal supplement treatment for depression or cognitive decline; clinical results vary by population and formulation."
resource: "https://nootropikler.com/nootropics/omega-3"
tags: ["Fatty Acid", "Cognition research"]
timestamp: 2026-11-11T00:00:00Z
category: "neurotrophic"
source: "Natural"
latin: "Docosahexaenoic acid / Eicosapentaenoic acid"
language: "en"
---

# Omega-3 DHA/EPA

*Docosahexaenoic acid / Eicosapentaenoic acid*

EPA and DHA are long-chain omega-3 fatty acids; DHA is an important brain membrane component. They are not a universal supplement treatment for depression or cognitive decline; clinical results vary by population and formulation.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Standard Form | Fish/Algae Oil |
| Dose used in research | Product- and study-specific |
| Safety | See detailed safety warnings |

> Correction 2026-11-11: Small positive trials were balanced with larger trials and reviews. Mandatory supplementation, product superiority, unverified synergy and preoperative stopping instructions were removed.

## What are Omega-3 DHA and EPA?

EPA and DHA are long-chain omega-3 fatty acids; DHA is an important brain membrane component. They are not a universal supplement treatment for depression or cognitive decline; clinical results vary by population and formulation.

ALA is the essential omega-3 fatty acid. Humans can synthesize small amounts of EPA and DHA from ALA, with limited conversion. DHA enters brain phospholipids, but it does not make up most brain fat and chronic deficiency cannot be assumed for everyone.

## Clinical Trials

Su 2003: In 28 patients with major depression, 6.6 g/day omega-3 added to usual treatment reduced depression scores more than placebo over eight weeks. This small double-blind trial proves neither monotherapy nor benefit in healthy people.

The accessed abstract does not explicitly verify randomization, so this is classified as a controlled human trial. The studied 6.6 g is not a personal recommendation or safe upper limit.

MIDAS 2010: In 485 adults aged 55+ meeting age-related cognitive decline criteria, 900 mg/day DHA improved some learning and memory tests versus placebo at 24 weeks. Working-memory and executive-function tests did not differ.

Selected tests do not establish global cognitive rejuvenation or Alzheimer prevention. A DHA trial cannot be generalized to every EPA/DHA mixture or all brain functions.

VITAL 2022: With 3424 participants assessed by phone and 794 in person, 1 g/day fish oil (840 mg EPA+DHA) showed no significant global cognitive benefit over 2–3 years. Pooled annual difference was −0.01 (95% CI −0.02–0.003; p=0.15).

Participants were generally healthy community-dwelling adults aged 60+. This null result for a product and follow-up is not a definitive judgment on every clinical group or lifelong dietary effect.

Cochrane 2021: 34 placebo comparisons included 1924 people. Symptom analysis of 33 studies/1848 people found SMD −0.40 (95% CI −0.64–−0.16), with very low certainty. The average difference of about 2.5 HDRS points was below the review's 3-point clinical importance threshold.

Statistical difference is not certain clinical benefit. Heterogeneity, possible bias and confidence intervals matter. There were 35 studies overall; 1848 people belong only to the symptom meta-analysis.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

When reading the label of omega-3 supplements, the total amount of EPA + DHA should be checked; fish oil capsule weight can be much higher than this.

## Safety and Side Effects

Gencer 2021 pooled 81,210 participants from seven randomized cardiovascular-outcome trials. Omega-3 was associated with higher atrial-fibrillation risk: HR 1.25 (95% CI 1.07–1.46). Relative increases were larger in trials using >1 g/day.

HR 1.25 is not an absolute increase of 25 percentage points. Between-trial dose comparisons do not define a personal safe threshold; the same magnitude cannot be assumed for every healthy user or formulation.

High-dose omega-3 is not risk-free for everyone. Large trials using 4 g/day in adults with cardiovascular disease or high risk found increased atrial fibrillation risk. Anticoagulants, pregnancy or surgery require medical review of dose and product.

NIH ODS: High doses may have antiplatelet effects, but most research in warfarin users found no significant change in anticoagulant status. This proves neither increased bleeding nor no risk for every product/drug pair; monitoring is assessed with the care team.

An antiplatelet mechanism alone does not quantify clinical bleeding. Nausea, reflux or diarrhea may occur; no frequency or guaranteed meal/coating prevention is given. Do not independently stop medicines or supplements before surgery.


## Frequently Asked Questions

### What do omega-3 DHA and EPA do?

EPA and DHA are long-chain omega-3 fatty acids; DHA is an important brain membrane component. They are not a universal supplement treatment for depression or cognitive decline; clinical results vary by population and formulation.

### What is the recommended daily dose for omega-3?

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

### What are the side effects of omega-3 supplements?

High-dose omega-3 is not risk-free for everyone. Large trials using 4 g/day in adults with cardiovascular disease or high risk found increased atrial fibrillation risk. Anticoagulants, pregnancy or surgery require medical review of dose and product.

### Is omega-3 supplement legal and easily available in Türkiye?

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

### When does the effect of omega-3 supplements begin?

No established timeframe

## Sources

- Grosso G, et al. (2014). Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. *Oxidative Medicine and Cellular Longevity*, 2014, 313570. [PubMed · PMID 24757497](https://pubmed.ncbi.nlm.nih.gov/24757497/)
- Su KP, et al. (2003). Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. *European Neuropsychopharmacology*, 13(4), 267–271. [PubMed · PMID 12888186](https://pubmed.ncbi.nlm.nih.gov/12888186/)
- Yurko-Mauro K, et al. (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimer's & Dementia*, 6(6), 456–464. [PubMed · PMID 20434961](https://pubmed.ncbi.nlm.nih.gov/20434961/)
- Calder PC (2016). Docosahexaenoic acid. *Annals of Nutrition and Metabolism*, 69(Suppl 1), 7–21. [PubMed · PMID 27842299](https://pubmed.ncbi.nlm.nih.gov/27842299/)
- Freeman MP, et al. (2006). Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. *Journal of Clinical Psychiatry*, 67(12), 1954–1967. [PubMed · PMID 17194275](https://pubmed.ncbi.nlm.nih.gov/17194275/)
- Kang JH, et al. (2022). Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial. *Alzheimer's & Dementia (New York, NY)*, 8(1), e12288. https://doi.org/10.1002/trc2.12288 [PubMed · PMID 35415212](https://pubmed.ncbi.nlm.nih.gov/35415212/)
- Appleton KM, et al. (2021). Omega-3 fatty acids for depression in adults. *The Cochrane database of systematic reviews*, 11(11), CD004692. https://doi.org/10.1002/14651858.CD004692.pub5 [PubMed · PMID 34817851](https://pubmed.ncbi.nlm.nih.gov/34817851/)
- Gencer B, et al. (2021). Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. *Circulation*, 144(25), 1981-1990. https://doi.org/10.1161/CIRCULATIONAHA.121.055654 [PubMed · PMID 34612056](https://pubmed.ncbi.nlm.nih.gov/34612056/)
- NIH Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/ [NIH Office of Dietary Supplements](https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/)

## Related nootropics

- [Lion's Mane](/okf/nootropics/lions-mane.md)
- [Phosphatidylserine](/okf/nootropics/phosphatidylserine.md)
- [Mg L-Threonate](/okf/nootropics/magnesium-l-threonate.md)
